Sherbrooke Park Advisers’s Bristol-Myers Squibb BMY Stock Holding History

Sherbrooke Park Advisers’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-25,756	Closed	-$1.16M	–	234
2025 Q3	$1.16M	Sell	25,756 -3,137	-11%	-$147K	0.54%	17
2025 Q2	$1.34M	Buy	+28,893	New	+$1.42M	0.58%	13
2024 Q3	–	Sell	-13,678	Closed	-$568K	–	931
2024 Q2	$568K	Buy	13,678 +5,867	+75%	+$263K	0.1%	360
2024 Q1	$424K	Sell	7,811 -5,093	-39%	-$259K	0.08%	428
2023 Q4	$662K	Sell	12,904 -26,034	-67%	-$1.37M	0.31%	111
2023 Q3	$2.26M	Buy	38,938 +21,638	+125%	+$1.33M	0.72%	9
2023 Q2	$1.11M	Buy	17,300 +12,400	+253%	+$831K	0.58%	29
2023 Q1	$340K	Sell	4,900 -11,000	-69%	-$776K	0.51%	81
2022 Q4	$1.14M	Buy	+15,900	New	+$1.2M	0.84%	14

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Sherbrooke Park Advisers's BMY Position: Q4 2025 in Review

Sherbrooke Park Advisers sold out of Bristol-Myers Squibb (BMY) in Q4 2025, closing a stake of 25,756 shares — an estimated $1.16M sold.

Sherbrooke Park Advisers first reported a position in BMY in Q4 2022 and held it in 9 quarters. The position peaked at $2.26M in Q3 2023. 2,448 funds tracked by Wall St. Rank hold BMY as of Q4 2025.

Sherbrooke Park Advisers reported no remaining Bristol-Myers Squibb position as of Q4 2025 after selling out during the quarter.
Sherbrooke Park Advisers sold 25,756 Bristol-Myers Squibb shares in Q4 2025, an estimated $1.16M.
Sherbrooke Park Advisers first reported a position in Bristol-Myers Squibb in Q4 2022 and held it in 9 quarters.
Sherbrooke Park Advisers's Bristol-Myers Squibb position peaked at $2.26M in Q3 2023.
2,448 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.